Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat
- PMID: 2884654
- DOI: 10.1111/j.1600-0773.1987.tb01740.x
Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat
Abstract
The effects of the novel substituted benzamide remoxipride on apomorphine induced behaviour in rats was investigated by means of an automatic holeboard apparatus. The ability of remoxipride to antagonise locomotion and gnawing induced by a high dose of apomorphine (5 mg/kg) and inhibition of exploration induced by a low dose of apomorphine (0.05 mg/kg) was tested. It was found that remoxipride in moderate doses potentiate locomotion and inhibit gnawing induced by the high dose of apomorphine while higher doses of remoxipride inhibits both apomorphine induced gnawing and locomotion. The inhibition of exploration following the low dose of apomorphine was not antagonised by remoxipride pretreatment. The results demonstrated that remoxipride has an interesting and unique profile of dopamine antagonistic effects in rat behavioural models.
Similar articles
-
The unique effect of remoxipride on dopamine utilization in the basal ganglia.Acta Physiol Scand. 1991 Apr;141(4):577-8. doi: 10.1111/j.1748-1716.1991.tb09121.x. Acta Physiol Scand. 1991. PMID: 1678908 No abstract available.
-
[Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].Arzneimittelforschung. 1985;35(8):1227-31. Arzneimittelforschung. 1985. PMID: 2866774 German.
-
Locomotion and stereotyped behaviours induced by 1-amino-3,5-dimethyladamantane (D 145) and apomorphine in the rat: a comparison.J Pharm Pharmacol. 1986 Jul;38(7):520-5. doi: 10.1111/j.2042-7158.1986.tb04627.x. J Pharm Pharmacol. 1986. PMID: 2875153
-
Neuropharmacological and behavioural properties of remoxipride in the rat.Acta Psychiatr Scand Suppl. 1990;358:21-6. doi: 10.1111/j.1600-0447.1990.tb05281.x. Acta Psychiatr Scand Suppl. 1990. PMID: 1978483 Review.
-
Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.CNS Drug Rev. 2001 Fall;7(3):265-82. doi: 10.1111/j.1527-3458.2001.tb00199.x. CNS Drug Rev. 2001. PMID: 11607043 Free PMC article. Review.
Cited by
-
Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility.BMC Genomics. 2015;16 Suppl 2(Suppl 2):S14. doi: 10.1186/1471-2164-16-S2-S14. Epub 2015 Jan 21. BMC Genomics. 2015. PMID: 25708048 Free PMC article. No abstract available.
-
Structural insights into mode of actions of novel natural Mycobacterium protein tyrosine phosphatase B inhibitors.BMC Genomics. 2014;15 Suppl 1(Suppl 1):S3. doi: 10.1186/1471-2164-15-S1-S3. Epub 2014 Jan 24. BMC Genomics. 2014. PMID: 24564493 Free PMC article.
-
Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.Drugs. 1990 Dec;40(6):863-79. doi: 10.2165/00003495-199040060-00008. Drugs. 1990. PMID: 1981869 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources